Thread: SLNO (MC $24 M) Rare Disease in Phase 3 a Potential Blockbuster =MASSIVE Undervalued

Results 1 to 2 of 2

  1. #1

    Default SLNO (MC $24 M) Rare Disease in Phase 3 a Potential Blockbuster =MASSIVE Undervalued

    Soleno (SLNO) is a new formed company through the merger between Capnia and the private Essentials (merger completed in march 2017) thats why its still undiscovered. SLNO has a potential Blockbuster in Phase 3 for the treatment of Prader Willi Syndrome a Rare Disease for which there is no approved treatments . This unknown low float stock which has a terrible low valuation of $24 million could be the next SRPT the stock should be valued way over $100+ million right now for their Phase 3 Program and in the Billion if the outcome of the Phase 3 trial is positive which expected by next year .MYOK and SRPT both rare disease companies hitting Billion Dollar Valuation after Phase 2 results in just 10 patients , you will not find a rare disease company below $100 million valuation with a potential blockbuster in phase 3 that shows how terrible undervalued this stock is .GL
  2. #2

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts